There are questions about vuso-vec’s supporting and confirmatory trials.
ApexOnco Front Page
Recent articles
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.